NCI Drug Dictionary
The NCI Drug Dictionary contains technical definitions and synonyms for drugs/agents used to treat patients with cancer or conditions related to cancer. Each drug entry includes links to check for clinical trials listed in NCI's List of Cancer Clinical Trials.
- CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T lymphocytes
A preparation of genetically modified lymphocytes comprised of CD62L-positive naïve and memory T cells (Tn/mem), that are transduced ex vivo with a self-inactivating (SIN) lentiviral vector expressing a hinge-optimized chimeric antigen receptor (CAR) specific for the CD19 antigen and containing CD28 and CD3 zeta signaling domains, and a truncated form of the human epidermal growth factor receptor (EGFRt), with potential immunostimulating and antineoplastic activities. Upon isolation of peripheral blood lymphocytes (PBLs), transduction of the CD62L-positive T lymphocytes, expansion ex vivo and administration, the CD19R(EQ)-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T cells target CD19-expressing tumor cells, thereby inducing selective toxicity in CD19-expressing tumor cells. CD19 antigen is a B-cell specific cell surface antigen expressed in all B-cell lineage malignancies. Devoid of both ligand binding domains and tyrosine kinase activity, EGFRt both facilitates in vivo detection of the administered T cells and can promote elimination of those cells upon a cetuximab-induced antibody dependent cellular cytotoxicity response. Tn/mem T cells include naïve T cells, central memory T cells (Tcm) and stem cell memory T cells (Tscm). CD19R(EQ) contains two point mutations in the immunoglobulin (Ig) G4 spacer region, thereby preventing recognition of the CAR by Fc receptors (FcRs). Check for active clinical trials using this agent. (NCI Thesaurus)
Synonym: CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T cells
CD19R(EQ)28zeta/EGFRt+ naive and memory T cells
CD19R(EQ)28zetaEGFRt+ Tn/mem cells